Abstract:The increasing prevalence of neurodegenerative diseases constitutes a significant challenge to public health systems globally. Consequently, the quest for efficacious preventive and therapeutic strategies has assumed center stage in public health discourse. Animal models serve as indispensable instruments in neurodegenerative disease research, offering foundational data that inform our understanding of the pathological mechanisms and contribute to the development of novel therapeutic paradigms. This manuscript delineates the methodologies for constructing animal models germane to prevalent neurodegenerative conditions such as Alzheimer’s Disease, Parkinson’s Disease, and Amyotrophic Lateral Sclerosis. The establishment of these models incorporates factors like genetic etiology, pathological signatures, and the temporal course of disease progression. Traditional techniques in model development frequently exhibit shortcomings in disease specificity, phenotypic stability, and alignment with the pathological evolution of human ailments. However, advancements in gene-editing technologies, notably CRISPR/Cas9, facilitate the emulation of human neurodegenerative disease pathologies with increased precision. This augments the relevance of animal models as instrumental tools in pharmaceutical development and the formulation of disease prevention strategies. In addition to conventional neurodegenerative animal models, the manuscript explores advancements in innovative models including chemical induction models, human brain tissue transplantation models, spontaneous models, and accelerated aging models. A focal point of the discourse is the transformative impact of gene-editing technologies on animal model development, with emphasis on the theoretical foundations and methodologies for creating polygenic breeding models and genetically diverse, gene-edited models. 1. Key gene-editing technologies applied in the domain of animal model creation encompass gene knock-in/knock-out, RNA interference (RNAi), and CRISPR/Cas9. Gene knock-in entails the integration of a target gene into a predetermined genomic location, while gene knock-out involves the excision of a specific gene, either entirely or partially. Both processes are predicated on homologous recombination, leveraging the innate capability of DNA molecules for homologous pairing and exchange to insert the target gene at precise chromosomal loci. 2. Complex human diseases frequently involve an array of genes or quantitative trait loci (QTL), each exerting a modest impact on the disease phenotype. When multiple QTLs are inherited, disease manifestation or predisposition may ensue. The advancement of mouse models for Alzheimer’s Disease epitomizes this intricate multi-gene or multi-locus modification process. As stronger genetic drivers and their combinations are identified, the selection and arrangement of divergent mouse strains can refine these models further. 3. The utility of genetically diverse gene-edited animal models lies in their ability to replicate human genetic variability by exploiting the phenotypic differences inherent in mice with assorted genetic backgrounds. The integration of gene-edited animal models into neurodegenerative disease research enhances our mechanistic understanding of these conditions. The manuscript elucidates emergent research avenues in gene-edited animal models, including the capabilities of polygenic models to emulate intricate disease states and the evolving role of comorbidity models. These tools are pivotal for a comprehensive understanding of disease pathogenesis, the elucidation of environmental and genetic interactions, the screening of pharmaceutical candidates, and the conception of innovative therapeutic interventions. Although existing models fail to capture the full complexity of human diseases, there is a rational expectation that ongoing technological innovations will ameliorate these limitations, thereby influencing the future trajectory of neurodegenerative disease research.

Development and validation of Alzheimer’s Disease Animal Model for the Purpose of Regenerative Medicine

Animal systems in the development of treatments for Alzheimer's disease: challenges, methods, and implications

Animal models of Alzheimer's disease and drug development

Translational animal models for Alzheimer's disease: An Alzheimer's Association Business Consortium Think Tank

Recent Advances: Decoding Alzheimer’s Disease with Stem Cells

Animal Models of Alzheimer's Disease: Current Strategies and New Directions.

Animal models of Alzheimer's disease: Applications, evaluation, and perspectives

Advance of Sporadic Alzheimer's Disease Animal Models

A Comprehensive Review on Preclinical Alzheimer's Disease Models: Evaluating their Clinical Relevance

Pathogenesis, Animal Models, and Drug Discovery of Alzheimer’s Disease

Model organism development and evaluation for late‐onset Alzheimer's disease: MODEL‐AD

Modeling neurodegenerative diseases using non-human primates: advances and challenges

Exploring advancements in early detection of Alzheimer's disease with molecular assays and animal models

Addressing the Discrepancies Between Animal Models and Human Alzheimer's Disease Pathology: Implications for Translational Research

Mitochondrial Transportation, Transplantation, and Subsequent Immune Response in Alzheimer's Disease: An Update

In vivo and ex vivo gene therapy for neurodegenerative diseases: a promise for disease modification

A review of the advances, insights, and prospects of gene therapy for Alzheimer's disease: A novel target for therapeutic medicine

Research on Alzheimer's Disease (AD) Involving the Use of In vivo and In vitro Models and Mechanisms

The Establishment and Application of Animal Models for Neurodegenerative Diseases

Advances in Research on Animal Models of Alzheimer's Disease

Insight into the emerging and common experimental in-vivo models of Alzheimer's disease